文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

COVID-19感染后肾功能下降

Kidney Function Decline After COVID-19 Infection.
PubMed 文献 · JAMA Netw Open · 2024-12-02
一句话结论队列研究显示COVID-19后eGFR年下降3.4%,高于肺炎后的2.3%,住院COVID-19者达5.4%;作者建议住院COVID-19者更密切监测肾功能。

该队列研究基于瑞典斯德哥尔摩SCREAM项目2018年2月1日至2022年1月1日数据,纳入COVID-19阳性检测或肺炎诊断前2年内至少1次eGFR测量的成人。COVID-19队列134 565人,肺炎队列35 987人。校正协变量后,两种感染后eGFR年下降均加速,COVID-19后为3.4%(95%CI 3.2%-3.5%),肺炎后为2.3%(95%CI 2.1%-2.5%);COVID-19住院者下降更严重(5.4%,95%CI 5.2%-5.6%),肺炎住院者则相似。作者认为住院COVID-19者应更密切监测肾功能,以早期诊断和优化管理慢性肾脏病。

要点

  • 校正协变量后,COVID-19后eGFR年下降3.4%(95%CI 3.2%-3.5%),肺炎后为2.3%(95%CI 2.1%-2.5%)。
  • COVID-19住院者eGFR年下降更严重,为5.4%(95%CI 5.2%-5.6%),肺炎住院者则相似。
  • COVID-19队列中位基线eGFR为94(IQR 79-107)mL/min/1.73m2,肺炎队列为79(IQR 61-92)mL/min/1.73m2。
  • 作者建议住院COVID-19者更密切监测肾功能,以早期诊断和优化管理慢性肾脏病,预防并发症和进一步下降。

适用人群与场景

  • 数据库内所有在COVID-19阳性检测或肺炎诊断前2年内至少有1次eGFR测量的住院和非住院成人。

处置流程与药物剂量

  • 作者建议:住院COVID-19者应更密切监测肾功能,以确保慢性肾脏病的早期诊断和优化管理,有效预防并发症和进一步下降。

研究设计与关键结果

  • 研究类型:队列研究,使用瑞典斯德哥尔摩SCREAM项目2018年2月1日至2022年1月1日的关联数据;统计分析于2023年6月至2024年10月进行。
  • COVID-19队列134 565人(女性74 819人[55.6%];中位[IQR]年龄51[37-64]岁),肺炎队列35 987人(女性19 359人[53.8%];中位[IQR]年龄71[56-81]岁)。
  • COVID-19队列中位(IQR)基线eGFR为94(79-107)mL/min/1.73m2,肺炎队列为79(61-92)mL/min/1.73m2。
  • 校正协变量后,两种感染后eGFR年下降均加速:COVID-19后为3.4%(95%CI 3.2%-3.5%),肺炎后为2.3%(95%CI 2.1%-2.5%)。
  • COVID-19住院者eGFR年下降更严重,为5.4%(95%CI 5.2%-5.6%),肺炎住院者则相似。

证据类型、等级与局限

  • 证据类型:队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,住院COVID-19者应接受更密切的肾功能监测,以确保慢性肾脏病的早期诊断和优化管理,从而有效预防并发症和进一步下降。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: COVID-19 infection has been associated with acute kidney injury. However, its possible association with long-term kidney function is not well understood.

OBJECTIVE: To investigate whether kidney function decline accelerated after COVID-19 compared with after other respiratory tract infections.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study used linked data from the Stockholm Creatinine Measurements (SCREAM) Project between February 1, 2018, and January 1, 2022, in Stockholm, Sweden. All hospitalized and nonhospitalized adults in the database with at least 1 estimated glomerular filtration rate (eGFR) measurement in the 2 years prior to a COVID-19 positive test result or pneumonia diagnosis were selected. Statistical analyses were conducted between June 2023 and October 2024.

EXPOSURE: COVID-19 and pneumonia (including influenza).

MAIN OUTCOMES AND MEASURES: Mean annual change in eGFR after COVID-19 and after pneumonia was calculated with a linear regression model.

RESULTS: The COVID-19 cohort comprised 134 565 individuals (74 819 females [55.6%]; median [IQR] age, 51 [37-64] years). The pneumonia cohort consisted of 35 987 individuals (19 359 females [53.8%]; median [IQR] age, 71 [56-81] years). The median (IQR) baseline eGFR was 94 (79-107) mL/min/1.73m2 for the COVID-19 cohort and 79 (61-92) mL/min/1.73m2 for the pneumonia cohort. After adjustment for covariates, both infections demonstrated accelerated annual eGFR decline, with greater magnitude of decline after COVID-19 (3.4% [95% CI, 3.2%-3.5%] after COVID-19; 2.3% [95% CI, 2.1%-2.5%] after pneumonia). This decline was more severe among individuals hospitalized for COVID-19 (5.4%; 95% CI, 5.2%-5.6%) but remained similar among those hospitalized for pneumonia.

CONCLUSIONS AND RELEVANCE: This cohort study found an association between COVID-19 and accelerated decline in kidney function, particularly after hospitalization, compared with pneumonia. People who were hospitalized for COVID-19 should receive closer monitoring of kidney function to ensure early diagnosis and optimized management of chronic kidney disease to effectively prevent complications and further decline.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Mahalingasivam V, Faucon AL, Sjölander A, et al. Kidney Function Decline After COVID-19 Infection. JAMA Netw Open. 2024. PMID: 39724377. doi:10.1001/jamanetworkopen.2024.50014

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。